AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

PRESCIENT THERAPEUTICS LTD

0.068

+0.0011.49%

Volume:3.48M

Turnover:242.04K

Market Cap:71.50M

PE:-10.00

High:0.073

Open:0.067

Low:0.067

Close:0.067

52wk High:0.125

52wk Low:0.041

Shares:1.05B

Float Shares:863.70M

Volume Ratio:3.41

T/O Rate:0.40%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.007

EPS(LYR):-0.007

ROE:-54.73%

ROA:-28.94%

PB:5.04

PE(LYR):-10.00

Loading ...

Overview Company News Filings

Concept

Pharmaceutical Companies-1.24%

Capital Flow

Inflow:

Outflow:

News

Prescient Therapeutics Ltd-Prescient Therapeutics - Extension of Share Purchase Plan

THOMSON REUTERS

Prescient Therapeutics Extends Share Purchase Plan Closing Date

MT Newswires Live

Prescient Therapeutics Ltd-Prescient Therapeutics - Extension of Share Purchase Plan

THOMSON REUTERS

Prescient Therapeutics Hits Dose Optimization Review Milestone in Cancer Drug Study

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigermarketf.com/stock/PTX.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PTX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PTX.AU\",,,,,undefined,":{"symbol":"PTX.AU","market":"AU","secType":"STK","nameCN":"PRESCIENT THERAPEUTICS LTD","latestPrice":0.068,"timestamp":1789711920000,"preClose":0.067,"halted":0,"volume":3477311,"delay":0,"changeRate":0.01492537313432837,"nameEN":"PRESCIENT THERAPEUTICS LTD","floatShares":863697911,"shares":1051514543,"eps":-0.0068,"marketStatus":"Not Yet Opened","change":0.001,"latestTime":"09-18 16:12:00 AEST","open":0.067,"high":0.073,"low":0.067,"amount":242043,"amplitude":0.089552,"askPrice":0.069,"askSize":135524,"bidPrice":0.068,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-0.0068,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789948800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.067,"openAndCloseTimeList":[[1789689600000,1789711200000]],"volumeRatio":3.408007798220076,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"PTX.AU","preClose":0.067,"auctionPrice":0.068,"auctionVolume":150000,"auction":3,"marketStatus":"盘后竞价","timestamp":1789711803924}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PTX.AU\",,,,,undefined,":{"symbol":"PTX.AU","floatShares":863697911,"roa":"-28.94%","roe":"-54.73%","lyrEps":-0.0068,"volumeRatio":3.408007798220076,"shares":1051514543,"dividePrice":0,"high":0.073,"amplitude":0.089552,"preClose":0.067,"low":0.067,"week52Low":0.041,"pbRate":"5.04","psRate":"20.72","week52High":0.125,"institutionHeld":0,"latestPrice":0.068,"committee":-0.992648,"eps":-0.0068,"divideRate":0,"volume":3477311,"delay":0,"ttmEps":-0.0068,"open":0.067,"prevYearClose":0.084,"prevWeekClose":0.068,"prevMonthClose":0.066,"prevQuarterClose":0.061,"fiveDayClose":0.068,"twentyDayClose":0.076,"sixtyDayClose":0.061,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTX.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PTX.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667569924","title":"Prescient Therapeutics Ltd-Prescient Therapeutics - Extension of Share Purchase Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2667569924","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667569924?lang=en_us&edition=fundamental","pubTime":"2026-09-15 07:00","pubTimestamp":1789426817,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nTUEBBQWSP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","PTX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665467673","title":"Prescient Therapeutics Extends Share Purchase Plan Closing Date","url":"https://stock-news.laohu8.com/highlight/detail?id=2665467673","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665467673?lang=en_us&edition=fundamental","pubTime":"2026-09-08 10:06","pubTimestamp":1788833182,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics  has extended the closing date of its share purchase plan  to Sept. 15 from Sept. 8, giving eligible shareholders more time to participate in the AU$7 million capital raising following delays in receiving documentation, according to a Tuesday filing with the Australian bourse.Eligible shareholders can apply under the SPP for up to AU$30,000 worth of new shares at AU$0.065 each, per the filing.The funds will be used to support the advancement of PTX-100 beyond the Dose Optimization Committee meeting, expected in December, and to guide the study's continuation and further development, the filing added.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4007","BK7067","BK7508","LENZ","PTX.AU","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665348989","title":"Prescient Therapeutics Ltd-Prescient Therapeutics - Extension of Share Purchase Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2665348989","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665348989?lang=en_us&edition=fundamental","pubTime":"2026-09-08 07:03","pubTimestamp":1788822214,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260907:nTUE8B6FQW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","PTX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664999896","title":"Prescient Therapeutics Hits Dose Optimization Review Milestone in Cancer Drug Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2664999896","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664999896?lang=en_us&edition=fundamental","pubTime":"2026-09-02 13:38","pubTimestamp":1788327489,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics  reached the pre-specified enrollment threshold for its first planned dose optimization committee review in a phase 2a study of its PTX-100 drug candidate in relapsed or refractory cutaneous T-cell lymphoma, according to a Wednesday filing with the Australian bourse.The company said 10 evaluable patients, or those who have completed four cycles of treatment, are now enrolled in each of the study's two dosing arms for 20 evaluable patients in total.The first dose optimization committee review remains on track for December, and enrollment in the study continues globally toward a full target of 40 evaluable patients.Cutaneous T-cell lymphoma is a type of immune system cancer where abnormal white blood cells migrate to and attack the skin.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","LENZ","PTX.AU","BK4007","BK4539","BK4139","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":4,"pageCount":1,"totalSize":13,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/PTX.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"Pharmaceutical Companies","id":"package_au_concept_yyswg","bkCode":"BK7508","changeRate":-0.012418}]}}